Serena Di Cosimo

Fondazione IRCCS Istituto Nazionale dei Tumori

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials”.

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

npj Breast Cancer(2022)10.1038/s41523-022-00430-0

N/A

0.417DataRank · unranked

8 citations

Zhuo Li, Daniel Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner +20 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature Communications(2023)10.1038/s41467-023-42635-2

N/A

0DataRank · unranked

17 citations

Aranzazu Fernández-Martínez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker +17 more

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open(2024)10.1016/j.esmoop.2024.103938

N/A

0DataRank · unranked

9 citations

M. Piccart-Gebhart, Shona Fielding, John Townend, D.W. Hillman, M. Colleoni +37 more

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

Annals of Oncology(2024)10.1016/j.annonc.2024.12.010

N/A

0DataRank · unranked

3 citations

Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti +18 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

UNC Libraries(2024)10.17615/6kd2-qh45

N/A

0DataRank · unranked

0 citations

A Fernandez-Martinez, Françoise Rothé, EP Winer, David Venet, I.E. Krop +17 more

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

UNC Libraries(2025)10.17615/kfcn-nf74

N/A

0DataRank · unranked

0 citations

Afshin Mashadi-Hossein, Kathleen Tenner, Lisa A. Carey, Zhuo Li, Heather Ann Brauer +20 more